An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.

The US drugmaker said it was informed by the Data Safety Monitoring Board that its vaccine had met statistical criteria ...

Will a hantavirus outbreak offset the regulatory risks weighing on Moderna stock? The path to recovery is far from certain.

CAMBRIDGE, Mass. - Moderna’s COVID-19 vaccine remained 93% effective against symptomatic illness six months after the second dose, but amid the ongoing spread of the highly contagious delta variant, ...

(NEXSTAR) – The Moderna COVID-19 remains effective even after 6 months, the company said in a Tuesday update on its ongoing clinical trials. The study looked at 33 healthy adult participants in the ...

After a large trial showed stronger protection, regulators are weighing whether Moderna’s mRNA vaccine could become a U.S.

Moderna said its combination vaccine targeting Covid and the flu was more effective than existing standalone shots for those viruses in a late-stage trial. The biotech company is the first to release ...

Moderna says its vaccine is 93% effective against symptomatic illness at six months (though this data collection ended before delta emerged in the U.S.). Moderna said its booster candidates also ...

Moderna’s new mRNA based seasonal flu vaccine is more effective than traditional flu shots at preventing flu, a late stage ...

NEW YORK (Reuters) - Moderna Inc respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the drugmaker said on Wednesday. In their clinical trials, GSK's ...

Moderna's mRNA-based flu vaccine outperformed a standard-dose shot by 26.6% in a late-stage trial, marking progress toward innovative influenza prevention methods.